Join Growin Stock Community!

Bioatla, inc.BCAB.US Overview

US StockHealthcare
(No presentation for BCAB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCAB AI Insights

BCAB Overall Performance

BCAB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCAB Recent Performance

-24.21%

Bioatla, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BCAB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCAB Key Information

BCAB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCAB Profile

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Price of BCAB

BCAB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCAB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.22
PB Ratio
2.68
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-541.05%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.22
PB Ratio
2.68
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-541.05%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BCAB's latest earnings report released?

    The most recent financial report for Bioatla, inc. (BCAB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCAB's short-term business performance and financial health. For the latest updates on BCAB's earnings releases, visit this page regularly.

  • How is BCAB's revenue growth?

    In the latest financial report, Bioatla, inc. (BCAB) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BCAB have?

    As of the end of the reporting period, Bioatla, inc. (BCAB) had total debt of 6.18M, with a debt ratio of 0.39. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BCAB have?

    At the end of the period, Bioatla, inc. (BCAB) held Total Cash and Cash Equivalents of 8.32M, accounting for 0.52 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BCAB's EPS continuing to grow?

    According to the past four quarterly reports, Bioatla, inc. (BCAB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCAB?

    Bioatla, inc. (BCAB)'s Free Cash Flow (FCF) for the period is -9.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 92.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.